تسلسل الإكسوم الكامل - Duo

This full exome sequencing test aims to identify gene sets for diagnosing rare genetic disorders by evaluating nearly all protein-coding genes in the human genome. It includes routine reanalysis and covers costs for up to two years.

• The description claims that the test may discover incidental genetic changes of medical importance but not directly related to the primary reason for exome sequencing.
• The description claims that Enigma Genomics will report any incidental results related to adult neurodegenerative disorders without available interventions.
• The description claims that incidental results are considered part of Enigma Genomics' duty to inform policy, and patients cannot opt out even if the result falls under secondary ACMG results.